ArticleScientific reports2026
Kv1.3 Channel inhibition by nanoformulated MeuKTx as a therapeutic strategy in breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer, particularly invasive and epithelial–mesenchymal transition (EMT)–associated phenotypes, remains a major therapeutic challenge. MeuKTx, a Kv1.3-targeting peptide derived from Mesobuthus eupeus venom, was nanoformulated using chitosan to improve peptide stability and cellular delivery. This study presents the first nano-encapsulation of MeuKTx (NP-MeuKTx) for anticancer evaluation. The resulting nanoparticles exhibited uniform morphology, nanoscale size, and high encapsulation efficiency. NP-MeuKTx exhibited significantly enhanced cytotoxicity compared with free MeuKTx. The IC₅₀ value of free MeuKTx in MCF-7 cells was greater than 400 pM, whereas NP-MeuKTx exhibited a markedly lower IC₅₀ of 25.3 pM. In MCF-7-EMT cells, the IC₅₀ of free MeuKTx was 85.32 pM, which was substantially reduced to 23.27 pM following NP-MeuKTx treatment. Migration assays demonstrated that NP-MeuKTx markedly suppressed cell migration in both MCF-7 and MCF-7-EMT cells, with significantly greater inhibition than free MeuKTx (p ≤ 0.0022). Flow cytometric analysis revealed that NP-MeuKTx induced the highest levels of apoptosis in both cell models, significantly exceeding the effects of free peptide (p = 0.0001). Furthermore, NP-MeuKTx strongly inhibited angiogenesis in HUVEC tube formation assays, significantly reducing branch points, total tube length, and mesh area compared with controls and free MeuKTx (p < 0.0001). Overall, these findings indicate that chitosan-based nanoformulation improves the functional anticancer activity of MeuKTx in breast cancer models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.